Abstract: Activated Ca ncer Ther apy ( ACT), al so know n a s Sonodyna mic Phot odynamic Ther apy ( SPDT) i s a nove l therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of phot odynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. Thi s case se ries of 115 pa tients w ith a v ariety of ca ncer di agnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of further investigation a s an ef fective and w ell to lerated t reatment fo r a w ide v ariety o f p rimary an d m etastatic tumours, including those refractory to chemotherapy.
INTRODUCTION
This c ase s eries of 115 pa tients w ith a variety of c ancer diagnoses outlines clinical outcomes over a 4 ye ar period of Activated Ca ncer T herapy (A CT) a lso known a s S onodynamic Photodynamic Therapy (SPDT) or t he Sonnelux Protocol. This is a novel therapeutic modality that utilises a nontoxic photosensitive agent with reported ultrasound-activated properties. This treatment centres around the development of a specific light and ultrasound activated sensitiser (Sonnelux-1) which has previously demonstrated tumour cell inhibition in animal studies, and m ay provide a new method of i nducing t argeted t umour c ell ne crosis. Ma ny of t he pa tients i ncluded in th is cas e s eries h ave ad vanced m etastatic can cer diagnoses, and m any have failed to respond to conventional management approaches. Num erous c ases a re r eported showing s ignificant e xtension of pre dicted m edian s urvival with reduced tumour mass and stable disease both clinically and on imaging.
BACKGROUND: ACTIVATED CANCER THERAPY

Photodynamic Therapy -Light Activated Therapy
Photodynamic Therapy (PDT) is an established therapeutic opti on for a va riety of pre -cancerous a nd malignant pathologies [1] [2] [3] [4] [5] . T he m ajority of P DT phot osensitive a gents possess a he terocyclic ring s tructure s imilar to that of c hlorophyll or t he ha em group i n ha emoglobin [6] , that c an b e administered via topical or s ystemic routes. The photosensitiser becomes activated by light energy applied from an LED or coherent laser emission source.
Following absorption of light at a specific wavelength by the photosensitiser, a transfer and translation occurs of li ght energy into a chemical reaction. In the presence of molecular oxygen t his produc es s inglet oxyge n ( 1 O 2 ) or s uperoxide (O 2 -), a nd i nduces cell d amage through di rect a nd i ndirect cytotoxicity [6] .
A va riety of phot osensitisers de monstrate s elective a bsorption in to malignant c ells, increasing th e p otential to target cytotoxicity [6, 7] and limit unwanted side-effects.
Photo-activation is however limited to surface pathology, or t umour m ass c apable of be ing ta rgeted via e ndoscopic access. T his i s due t o a bsorption of l ight into s urrounding tissue, which creates limitation on pe netrance and the d epth of photosensitiser activation. The use of new photosensitisers sensitive t o l onger wa velengths of l ight i ncreases de pth of penetration [8] , but effective non-invasive treatment of d eep tumour sites remains problematic.
S onodynamic Th erapy -U ltrasound Ac tivated Therapy
Ultrasound is a mechanical wave with periodic vibrations of pa rticles i n a continuous, e lastic m edium a t fre quencies equal to or gre ater than 20 kHz . It is not only p erceived as safe, but has excellent tissue penetrating ability without major attenuation of i ts energy [9, 10] . T herefore the potential medical application of ult rasound has been evaluated extensively and has lead to the routine use of ul trasound for di agnostic imaging of soft tissue [11] .
Ultrasound Ac tivated T herapy (s onodynamic t herapy), the ultrasound dependent enhancement of cytotoxic activities of certain compounds (s onosensitisers), is an a ttractive m odality f or can cer tr eatment w ith p otential to f ocus th e u ltrasound energy on t umour s ites buried de ep in tissues and to locally activate a preloaded sonosensitiser.
The effect can be localised by focusing the ultrasound on a defined region and choosing compounds with tumour affinity [12] [13] [14] , c ausing e nhanced c ytotoxicity at pa thological sites with minimal damage to peripheral healthy tissue.
Potentiated c ytotoxicity by ul trasound wa s fi rst de monstrated whe n m ouse l eukemia L 1210 c ells we re e xposed to continuous wave ultrasound (2 M Hz, 10 W/ cm2) while suspended i n ni trogen m ustard s olution in vitro. M ice subsequently inoculated with these cells had longer survival times than control animals that received cells exposed to the drug but not ultrasound [15] .
Following this, the application of low-level ultrasound to a biological target was found to potentiate chemotherapeutic cell killing with adriamycin and diaziquone [16] . In vivo, this combined drug a nd ultrasound treatment resulted in s tatistically significant reductions in tumor volume of uterine cervical s quamous c ell c arcinoma implanted i n t he cheek pouc h of th e S yrian h amster compared to the ch emotherapeutic alone. T he ult rasound a pplied w ithout t he chemotherapy agent w as non-c ytotoxic and produc ed ne gligible temperature elevation.
The photodynamic s ensitisers have also been s tudied for ultrasound-activated prope rties. T hey ha ve t he be nefit of being non-toxic unless activated and have been demonstrated to have tumour localizing properties [6, 7] . H ematoporphyrin, a c ommonly us ed phot o-sensitiser e nhanced the k illing of mouse sarcoma and rat ascites 130 tumor cells exposed in vitro to ultrasound (1.92 MHz) at intensities of 1.27 and 3.18 w/cm2, from 30% and 50% to 99% to 95% respectively [17] .
Possible cytotoxic m echanisms include ge neration of sonosensitiser-derived radicals which initiate chain peroxidation of membrane lipids via peroxyl and/or alkoxyl radicals, the phys ical de stabilization of the cell membrane by the sonosensitizer thereby rendering the cell more susceptible to shear forc es and c avitation e ffects or ul trasound e nhanced drug transport across the cell membrane (sonoporation) [14, 18, 19] .
SONNELUX -1 -A DUAL ACTIVATION AGENT
Light and Ultrasound Activation
Sonnelux-1 is a metallo-chlorin c omplex, c ontaining a highly purified mixture of several chlorophyllins, each with a different side chain and an average molecular weight of 942. Sonnelux-1 has photo-activation properties and has also been demonstrated to be extremely sensitive to ultrasound [20] .
Safety s tudies, including L C50 s tudies of S onnelux-1 as determined in zebrafish, reveal that Sonnelux-1 is essentially non-toxic. No zebrafish death is no ted at the maximum soluble concentration of the sonosensitiser (data pending publication). 7 S onnelux-1 is registered as non-hazardous according to OSHA standards and EU directives.
Sonnelux-1 Ani mal Stud ies D emonstrating Do seDependent Ultrasound Activated Tumour Cytotoxicity
Sonnelux-1 ha s d emonstrated s ignificant tumour c ell cytotoxicity fo llowing ult rasound-activation us ing a mouse S-180 S arcoma m odel [21] . F ollowing t reatment, t umour volume was monitored. Significant tumour growth inhibition was seen in the group that was administered both ultrasound and Sonnelux-1 with s ignificant (p<0.01) reduction in m ean tumour we ight (s ee F ig. 2). No s ignificant di fference occurred with ultrasound or sonnelux administration alone. Significantly, cytotoxicity increased in a dos e-dependent manner from 0.3W/cm2 to 1.2W/cm2 (see Fig. 3 ). Histology showed c oagulated ne crosis or m etamorphic ti ssue wh ich started within 2 hours of ultrasound activation [21] .
Tumour c ytotoxicity w as also re ported wh en a bonebarrier w as pl aced be tween t he u ltrasound e xposure s ource and t he a nimals unde r s tudy [21] . S tudies ha ve pre viously supported propogation of ult rasound through bone s tructure [22] , and this provides further support for the possibility that sufficient u ltrasound a ctivation c an be a chieved for t umour sites distant or within bone structure.
METHOD Activated Cancer Therapy Protocol
Sonnelux Protocol
Sonnelux-1 is administered slowly over 2 to 5 hours sublingually to provi de s ustained l ow pla sma c oncentration. Forty eight hours after s ublingual administration the pa tient is exposed to a light bed containing 48 panels of LED's emitting a c ombination of vi sible and i nfra-red li ght at t he frequencies 660nm and 940nm (+/-30nm).
No photosensitivity from norm al ambient light, artificial or na tural h as be en note d but a s a pre caution pa tients are advised not to stay in direct sunlight for periods over half an hour for one we ek fo llowing S onnelux-1 a dministration. Light b ed exposure time varies w ith s horter exposure duration in cases with larger tumour load.
Ultrasound is then applied at 1W/cm 2 and a frequency of 1MHz at sites of known malignant disease, with time titrated on a case by case basis.
Light and ultrasound activation is repeated on three consecutive days, and the s ame process of S onnelux-1 administration fol lowed by l ight a nd ul trasound e xposure i s repeated after one week to complete a treatment cycle.
Ozone au to-haemotherapy is ad ministered i mmediately before light bed exposure, a iming to increase P 02 at the tumour site. Clinically, this has been observed to significantly increase the tumour cytotoxic effect of SPDT.
A c ourse of ora l de xamethasone i s a dministered t o patients dependent on tumour type, background physical status and total tumour volume. Alongside SPDT protocol, patients underwent s upportive nut ritional s upplementation de termined on a case by case basis. 
Data Collection
Details we re c ollated of 115 c onsecutive pa tients who received SPDT, including hospital diagnosis, previous treatment, tumour staging and expected survival in months based on Oncologist opinion a t initial consultation, wh ere known . Patients w ere rout inely fo llowed up one month pos t treatment and s ubsequently a t re gular intervals. Clinical note s were reviewed and telephone contact was attempted to optimize data collation.
Results have been tabulated for comparison and a series of 3 cases are outlined in greater detail.
RESULTS
All pa tient da ta i s a nonymously di splayed i n t he s ummary table (see Appendix 1) according to primary diagnosis site. Patient data has only been graphically presented when a predicted m edian s urvival is known. Of t hose pa tients still alive, onl y t hose who ha ve e xceeded t he pre dicted s urvival data are included in graphical representation.
Many patients are alive at the time of writing; therefore survival benefit is unknown and has been given in months up to the time of writing.
Case Reports
Case 1. Non Small-Cell Lung Cancer
This 80 year old female patient presented in August 2005 with a n i noperable non s mall-cell l ung c ancer i n t he le ft lung. She had refused palliative radiotherapy and at that time had be en g iven a pre dicted median s urvival of 6 m onths. Sonnelux-1 prot ocol S PDT w as c ompleted i n S eptember 2005. F ollowing treatment s he d eveloped a n i nter-scapula ache, but tolerated the treatment well. Until March 2007 s he had stable disease, as determined by r egular chest x-rays. In June 2007 she was demonstrated to have tumour progression Key: S = surgery, C= chemotherapy, R= radiotherapy, Ref= patient declined specified treatment, mets= metastasis, ? = data not known, E R= o estrogen r eceptor, FU= f ollow u p, GBM= gliobastoma multiforme, TCC= transitional cell carcinoma, pt number 59 allocated blank in error therefore not included in data table, HL= Hodgkin's Lymphoma, NHL= nonHodgkin's Lymphoma, NSCLC= non small cell lung cancer.
and unde rwent a s econd c ourse of S onnelux-1 prot ocol a t that ti me. S he t olerated t he second c ourse w ell a nd a t the time of writ ing (F ebruary 2009) s he s till ha s s table di sease on chest x-rays and is symptom free, with a good qua lity of life.
Case 2. Brain Tumour -Ependymoma
This 50 ye ar old female patient presented in April 2008, with a massive ependymoma first diagnosed in April 2003 . At first consultation her c linical s tate was poor, with a predicted median survival time of 6 months. She had previously undergone surgical de-bulking and whole brain radiotherapy. She ha d re fused m anagement wit h T emozolamide. S onnelux-1 protocol was performed in April 2008. Dexamethasone was prescribed for the treatment course (2mg twice a day). A month a fter treatment s he fe lt we ll e nough t o go on a 2 month holiday abroad. She has remained relatively symptom free. A further course of sonnelux-1 protocol was performed in Oc tober 2008. Repeat CT s cans i n D ecember 2008 showed that the tumour had decreased in size.
Case 3. Non-Hodgkin's Lymphoma
This 60 ye ar ol d fe male pa tient pre sented foll owing a recurrence of non-Hodgki n's lymphoma which was resistant to s econd li ne c hemotherapy. Sonnelux-1 prot ocol S PDT was completed in July 2005. At the time of writing, she is in full remission and has no re currence of he r tumour, with no other active treatment having been carried out.
DISCUSSION
Activated Cancer T herapy us ing S onnelux prot ocol shows significant promise over a 4 ye ar period as a safe and well tolerated non-invasive treatment even in advanced metastatic cancer. Extension in median survival times have been reported in a number of pa tients with a variety of c ancer diagnoses. There a re s everal pa tients still a live w ith r educed tumour mass and stable disease both clinically and on imaging. No adverse events w ere no ted following administration of Sonnelux-1.
Second and subsequent courses of ACT may have further benefit i n reducing t umour m ass and inhibiting t umour cell growth wi thout t he t otal dos e l imitations of ra diotherapy. Initial obs ervation s uggests that for pa tients w ith e xtensive tumour m ass it i s be tter t olerated t o unde rtake A CT us ing shorter c ycles of li ght and ul trasound a ctivation wit h de xamethsone c over. This approach controls t he a cute i nflammatory re sponse de monstrated on excision bi opsy in pre vious a nimal s tudies [21] a nd t hose s een in t his c ase s eries with initial inflammatory changes at tumour sites.
While th e inflammatory p hase m ust b e co ntrolled, p reclinical studies s uggest t hat successful t reatment outcome following P DT is c ritically de pendent on t he contribution from the host's acute-phase inflammatory response [23] .
It i s s uggested that unl ike i mmunologically s ilent ge notoxic da mage produc ed by ra diotherapy and c hemotherapy, photo-oxidative cytotoxic lesions generated by P DT are extra-nuclear an d r esult in a r apid c ell d eath that a lerts the host's innate im mune s ystem. [24] . N eutrophil m obilisation and i nnate immune c ell activation a re re sponsible for the development of t umor antigen-specific a daptive i mmune cascades th at co ntribute to th e er adication o f P DT-treated cancers. T his is fur ther s upported by in vitro s tudies wh ich established that tumour cells treated by PDT can be used for generating potent vaccines against cancers of the same origin [25] .
Exacerbation of bony m etastasis pain has been recorded, often foll owed by a re duction or r esolution of pre -existing bony pa ins. It t herefore a ppears t hat s ufficient ul trasound activation of Sonnelux-1 can occur within and distal to bony structures t o achieve tumour c ell i nhibition. T his fi nding is supported by pre vious animal s tudies [21] a nd the improvement in s ymptoms and CT ap pearance o f a p atient w ith a large intracranial ependymoma.
There also appears to be a potential role for ACT in neoadjuvant c ancer tr eatment, w ith n ecrotic tissue o n excision biopsy at tumour sites occurring within this case series.
Tumour hypoxi a ha s b een found t o be a c haracteristic feature in many solid tumours [26] . It has been demonstrated that tumor hypoxia, either pre-existing or a s a result of oxygen depletion during photodynamic therapy can significantly reduce the e ffectiveness of P DT-induced cell kil ling [27] . This study reported that when PDT is combined with hyperoxygenation, t he hypoxi c condition c ould b e improved a nd the cell killing rate at various time points after ACT could be significantly enhanced [27] .
Previously it has been shown in arteriopathic patients that ozone au tohemotherapy h as a therapeutic p otential b y increasing oxygen delivery in hypoxic tissues [28] . Clinically, it appears that gre ater tumour re sponse is s een wit h A CT following o zone a utohaemotherapy. This may r elate to a n increase in PaO2 in the tumour microenvironment.
Unlike other cancer treatment modalities no bone marrow suppression has be en noted following A CT. P atients underwent pre and post routine blood testing. Although not statistically assessed, ha emoglobin, t otal whit e cell count a nd platelet c ount appear unc hanged t hroughout t he t reatment and follow up period.
CONCLUSION
ACT (S PDT) wa rrants furt her i nvestigation as a noninvasive, w ell-tolerated and clinically effective targeted cancer treatment capable of tumour cell necrosis at both superficial and d eep m alignant sites. There is in creasing ev idence supporting t he mechanism of a ction of Ac tivated Cancer Therapy us ing l ight a nd ul trasound a nd t his c ase s eries reports on several patients with significant extension in median survival ti mes wit h a va riety of c ancer di agnoses, s howing reduced tumour m ass and s table disease bo th c linically and on radiographic imaging.
